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Background: Lung cancer is increasingly understood as
a disease made up of genomically defined subtypes
requiring distinct treatment strategies. We hypothesize
that young age at diagnosis (< 40 years) is a clinical
characteristic associated with an increased chance for a
targetable genomic alteration (GA). Our study will pro-
spectively characterize the somatic and germline geno-
mics of young lung cancer.
Method: Accrual opened in July 2014. Patients (pts) are
eligible if diagnosed with bronchogenic lung cancer
<age 40. The study website, allows for virtual con-
senting and remote participation from anywhere in the
world. We defined 7 GA of interest based on the Lung
Cancer Mutation Consortium (LCMC) (EGFR, KRAS,
HER2, BRAF, ALK, ROS1, RET). We aim to show the
prevalence of targetable GA in our stage 4 adenocarci-
noma (AC) pts will be greater in our population
compared to the LCMC, with an increase from 35% to
50%; and an improvement in use of targeted therapy
from 22% to 40%. Study subjects without a known
genotype undergo genomic profiling with the Founda-
tionOne test.
Results: Preliminary results of 71 pts with stage 4 AC
show that 82% have either an ALK re-arrangement
n¼32 (45%), an EGFR activating mutation n¼17 (24%),
a ROS1 fusion n¼5 (7%), a RET fusion n¼2 (3%) or a
HER2 mutation n¼2 (3%). Other GA of interest in those
with AC includes TP53, ATM and BRCA2 mutations. 49%
of our accrual has come from web based consenting. The
majority of subjects have come from North America and
Europe; and we would like representation from Latin
America.Conclusion: Thus far in our prospective series our re-
sults have far exceeded our statistical expectations,
with 82% of our stage 4 AC pts having an actionable
mutation. We have defined a genomically enriched
subtype of lung cancer and laid the groundwork for
further studies of germline and environmental lung
cancer risk factors. We are planning a large-scale Case
Control study of the Epidemiology of YLC. Web based
consenting is a feasible method of bringing research to
the patient.
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Background: Darbepoetin alfa (DA) is an erythropoi-
esis-stimulating agent (ESA) that has been shown to in-
crease hemoglobin levels and reduce the rate of
transfusions in patients with chemotherapy-induced
anemia (CIA). Most studies have not shown an associa-
tion between ESA use and poor outcomes, but some
clinical trials have reported increased mortality and/or
tumor progression. This trial was therefore designed to
address the safety of DA for CIA in patients with non-
small cell lung cancer (NSCLC).
Method: Study 20070782 is a randomized, double-
blind, noninferiority trial to compare DA with placebo,
and is enrolling patients with NSCLC with CIA. Eligible
patients are  18 years old with Eastern Cooperative
Oncology Group (ECOG) status  1, stage IV NSCLC, no
prior adjuvant/neoadjuvant NSCLC therapy,  2 cycles
